Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities.

IF 8.9 Journal of pharmaceutical analysis Pub Date : 2025-01-01 Epub Date: 2024-08-27 DOI:10.1016/j.jpha.2024.101084
ShanShan Hu, Zahra Batool, Xin Zheng, Yin Yang, Amin Ullah, Bairong Shen
{"title":"Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities.","authors":"ShanShan Hu, Zahra Batool, Xin Zheng, Yin Yang, Amin Ullah, Bairong Shen","doi":"10.1016/j.jpha.2024.101084","DOIUrl":null,"url":null,"abstract":"<p><p>Protozoan infections (e.g., malaria, trypanosomiasis, and toxoplasmosis) pose a considerable global burden on public health and socioeconomic problems, leading to high rates of morbidity and mortality. Due to the limited arsenal of effective drugs for these diseases, which are associated with devastating side effects and escalating drug resistance, there is an urgent need for innovative antiprotozoal drugs. The emergence of drug repurposing offers a low-cost approach to discovering new therapies for protozoan diseases. In this review, we summarize recent advances in drug repurposing for various human protozoan diseases and explore cost-effective strategies to identify viable new treatments. We highlight the cross-applicability of repurposed drugs across diverse diseases and harness common chemical motifs to provide new insights into drug design, facilitating the discovery of new antiprotozoal drugs. Challenges and opportunities in the field are discussed, delineating novel directions for ongoing and future research.</p>","PeriodicalId":94338,"journal":{"name":"Journal of pharmaceutical analysis","volume":"15 1","pages":"101084"},"PeriodicalIF":8.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786068/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical analysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jpha.2024.101084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Protozoan infections (e.g., malaria, trypanosomiasis, and toxoplasmosis) pose a considerable global burden on public health and socioeconomic problems, leading to high rates of morbidity and mortality. Due to the limited arsenal of effective drugs for these diseases, which are associated with devastating side effects and escalating drug resistance, there is an urgent need for innovative antiprotozoal drugs. The emergence of drug repurposing offers a low-cost approach to discovering new therapies for protozoan diseases. In this review, we summarize recent advances in drug repurposing for various human protozoan diseases and explore cost-effective strategies to identify viable new treatments. We highlight the cross-applicability of repurposed drugs across diverse diseases and harness common chemical motifs to provide new insights into drug design, facilitating the discovery of new antiprotozoal drugs. Challenges and opportunities in the field are discussed, delineating novel directions for ongoing and future research.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
探索对抗人类原生动物疾病的创新药物再利用策略:进展、挑战和机遇。
原生动物感染(如疟疾、锥虫病和弓形虫病)对全球公共卫生和社会经济问题造成相当大的负担,导致高发病率和死亡率。由于治疗这些疾病的有效药物有限,而这些疾病又具有破坏性的副作用和不断升级的耐药性,因此迫切需要创新的抗原虫药物。药物再利用的出现为发现治疗原生动物疾病的新疗法提供了一种低成本的方法。在这篇综述中,我们总结了各种人类原生动物疾病药物再利用的最新进展,并探讨了确定可行的新治疗方法的成本效益策略。我们强调了不同疾病中重新用途药物的交叉适用性,并利用常见的化学基序为药物设计提供了新的见解,促进了新的抗原虫药物的发现。讨论了该领域的挑战和机遇,描绘了正在进行和未来研究的新方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Synergistic cell membrane-coated ECL-DNA biosensor for specificity-enhanced drug lead evaluation. Establishment of an at-line nanofractionation-based screening platform for rapid identification of influenza PAN/PAN I38T inhibitors from Artemisiae Argyi Folium. CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability. Breaking the boundaries of affinity selection-mass spectrometry: From ligand screening to target-ligand interaction insights. Advances in aptamer technology for target-based drug discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1